Compare NPWR & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NPWR | RNA |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.9M | 226.3M |
| IPO Year | N/A | 2025 |
| Metric | NPWR | RNA |
|---|---|---|
| Price | $2.03 | $13.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 20 |
| Target Price | $3.50 | ★ $69.26 |
| AVG Volume (30 Days) | ★ 962.4K | 141.7K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $88.12 |
| Revenue Next Year | N/A | $18.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.46 | $11.95 |
| 52 Week High | $5.20 | $73.06 |
| Indicator | NPWR | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 53.46 | 38.90 |
| Support Level | $1.58 | $12.56 |
| Resistance Level | $2.17 | $13.97 |
| Average True Range (ATR) | 0.22 | 0.45 |
| MACD | -0.02 | 0.25 |
| Stochastic Oscillator | 37.12 | 28.68 |
NET Power Inc is a clean energy technology company that has developed a novel power generation system, which it refers to as the NET Power Cycle, designed to produce clean, reliable, and low-cost electricity from natural gas while capturing virtually all atmospheric emissions. The company's business model is to license its technology to customers and enable them to build, own, and operate facilities that utilize the Net Power Cycle. It has conducted a successful demonstration of its technology at the La Porte Demonstration Facility and is developing a utility-scale power plant in Texas named Project Permian.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.